|
[Related PubMed/MEDLINE] Total Number of Papers: 60
|
|
|
[Display Entries]
|
|
[Entries Per Page]
|
per page
|
|
Page Control
|
|
Page: of
|
|
|
|
Abbreviation |
: SD |
Long Form |
: solvent/detergent |
|
No. |
Year |
Title |
Co-occurring Abbreviation |
1 |
2017 |
Comparison of haemostatic function of PAS-C-platelets vs. plasma-platelets in reconstituted whole blood using impedance aggregometry and thromboelastography. |
PAS |
2 |
2017 |
Resuscitation with Pooled and Pathogen-Reduced Plasma Attenuates the Increase in Brain Water Content following Traumatic Brain Injury and Hemorrhagic Shock in Rats. |
BBB, FFP, OCTA |
3 |
2015 |
TnBP⁄Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus. |
HCV, HCV |
4 |
2014 |
Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada. |
FFP, QALYs |
5 |
2013 |
A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France. |
AEs, FFP, MB |
6 |
2013 |
[Clinical use of virally inactived plasma. The experience of Blood Transfusion Unit in Mantova, Italy]. |
FFP, MB |
7 |
2011 |
A comparison of methods of pathogen inactivation of FFP. |
MB |
8 |
2011 |
Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura. |
ITP, IVIG-L, PID |
9 |
2011 |
The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma. |
--- |
10 |
2010 |
[New cross-sectional guidelines of the German Medical Association for hemotherapy with fresh frozen plasma. Evidence-based recommendations for risk-benefit assessment]. |
PPSB |
11 |
2009 |
Recommendations for the use of therapeutic plasma. |
HUS, TTP |
12 |
2008 |
[Solvent-detergent viral inactivation of minipools of plasma for transfusion, cryoprecipitate and cryo-poor plasma in single-use bag systems]. |
--- |
13 |
2007 |
Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma. |
HIC |
14 |
2007 |
Virus-inactivated plasma - Plasmasafe: a one-year experience. |
APTT, FFP, MB, PT, TTP |
15 |
2006 |
Solvent-detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. |
--- |
16 |
2006 |
Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. |
--- |
17 |
2006 |
Universal pathogen-reduced plasma in elective open-heart surgery and liver resection. |
--- |
18 |
2006 |
Update on pathogen reduction technology for therapeutic plasma: an overview. |
FFP, MBLT, PLT, PRT, RLT, TRALI, vWF |
19 |
2006 |
Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product. |
BPV, BVDV, CPV, EMC, HAV, HIV, LE, NLE, PRV |
20 |
2005 |
SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation. |
SARS-CoV |
21 |
2005 |
Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48 h after thawing. |
FFP, RT |
22 |
2004 |
Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. |
CSP, FFP, MB, PEX, PS, TTP, VWF |
23 |
2004 |
Evidence-based medicine for apheresis: an ongoing challenge. |
TTP |
24 |
2003 |
Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). |
IgG, IGIV |
25 |
2003 |
The Norwegian Plasma Fractionation Project--a 12 year clinical and economic success story. |
--- |
26 |
2003 |
Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. |
DAT |
27 |
2003 |
Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. |
DVTs, PEX, TTP, VTE |
28 |
2002 |
Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. |
FFP, FVIII, HCV, HIV, MBP, SDP |
29 |
2000 |
Viral safety of solvent/detergent-treated plasma. |
--- |
30 |
1999 |
A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. |
FFP |
31 |
1999 |
Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. |
FFP, TTP |
32 |
1998 |
A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. |
FIX |
33 |
1998 |
A randomized trial of solvent/detergent and standard fresh frozen plasma in the treatment of the coagulopathy seen during Orthotopic Liver Transplantation. |
FFP, OLT, PTT, SDFFP |
34 |
1998 |
Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. |
DH, SDDH, SDP |
35 |
1998 |
Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. |
FFP |
36 |
1997 |
Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses. |
HBV, PCR |
37 |
1997 |
At least three hepatitis C virus strains implicated in Swedish and Danish patients with intravenous immunoglobulin-associated hepatitis C. |
--- |
38 |
1997 |
Cryoprecipitate prepared from plasma virally inactivated by the solvent detergent method. |
FFP, VWD, vWF |
39 |
1996 |
Clinical experience with Octagam, a solvent detergent (SD) virus inactivated intravenous gammaglobulin. |
--- |
40 |
1996 |
Virus validation studies of immunoglobulin preparations. |
--- |
41 |
1995 |
An outbreak of hepatitis A among Irish haemophiliacs. |
CI |
42 |
1995 |
Competitive ELISA to evaluate the immunogenicity of double-virus-inactivated factor VIII in rabbits. |
--- |
43 |
1994 |
Hepatitis A in French hemophiliacs. |
HA, HAV, HB |
44 |
1994 |
Hepatitis A virus transmission by blood products in the United States. Transfusion Safety Study Group. |
--- |
45 |
1994 |
Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate. |
HAV |
46 |
1994 |
Investigation of an outbreak of hepatitis A in Irish haemophilia A patients. |
--- |
47 |
1994 |
Protocol and preliminary results of a clinical study for comparison of solvent/detergent-inactivated plasma VIP versus FFP with special consideration of the balance of hemostasis. |
APL, DIC, MAC, PS, VIP |
48 |
1994 |
Viral safety of solvent/detergent-treated blood products. |
HAV, HBV, HIV, NANBHV |
49 |
1994 |
Virus validation of plasma-derived products produced by Pharmacia, with particular reference to immunoglobulins. |
HAV, HIV-1 |
50 |
1994 |
Von Willebrand factor multimers in virus-inactivated plasmas and F VIII concentrates. |
FFP, VWD, vWF |
51 |
1994 |
[Activity and concentration determinations of coagulation factors in conventional and virus-inactivated coagulation-active plasma]. |
FFP, MB |
52 |
1994 |
[Sensitivity studies on the demonstration of HIV-1 particles using RT HIV-1 PCR in pooled plasma before virus inactivation]. |
PCR |
53 |
1994 |
[Virus inactivated plasma]. |
MB, TnBP |
54 |
1993 |
Inactivation of viruses in fresh-frozen plasma. |
FFP, MB |
55 |
1993 |
Viral safety of solvent-detergent treated blood products. |
AHF, HBV, HCV, HIV, NANBHV, VSV |
56 |
1993 |
[Indications for fresh frozen plasma: evaluation of virus inactivating preparations]. |
FFP |
57 |
1992 |
Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity. |
FVIII, FVIII, VHP, VWD |
58 |
1990 |
Biochemical and physical properties of a solvent-detergent-treated fibrin glue. |
--- |
59 |
1988 |
Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma. |
PCC |
60 |
1988 |
Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates. |
--- |
|